| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
8,290,000 |
| Market
Cap: |
18.65(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$2.24 - $4.38 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Lumos Pharma is a clinical-stage biopharmaceutical company. Co. is engaged in developing its clinical program and focused on identifying, acquiring, developing, and commercialization products and new therapies for people with rare diseases. Co.'s pipeline is focused on the development of an orally administered small molecule, LUM-201, which is a growth hormone (GH) secretagogue, also called ibutamoren, for rare endocrine disorders where injectable recombinant human growth hormone is approved. Co.'s small-molecule product candidates, indoximod, NLG802 (a prodrug of indoximod) and NLG919 (a direct IDO1 enzymatic inhibitor) are indoleamine-2, 3-dioxygenase pathway inhibitors.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
12,789 |
| Total Buy Value |
$0 |
$0 |
$0 |
$96,371 |
| Total People Bought |
0 |
0 |
0 |
3 |
| Total Buy Transactions |
0 |
0 |
0 |
7 |
| Total Shares Sold |
2,214 |
2,652 |
6,059 |
10,074 |
| Total Sell Value |
$6,144 |
$7,472 |
$18,391 |
$48,860 |
| Total People Sold |
1 |
1 |
1 |
1 |
| Total Sell Transactions |
1 |
2 |
3 |
6 |
| End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Langren Carl W. |
Chief Financial Officer |
• – – |
2021-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
939 |
12,177 |
|
- |
|
| Deerfield Private Design Fund Iii, L.p. |
*Possible Member of 10% Group |
– – • |
2021-01-08 |
4 |
S |
$22.24 |
$2,376,099 |
I/I |
(106,512) |
784,568 |
|
54% |
|
| Deerfield Private Design Fund Iii, L.p. |
*Possible Member of 10% Group |
– – • |
2021-01-07 |
4 |
S |
$24.35 |
$396,821 |
I/I |
(16,172) |
891,080 |
|
56% |
|
| Deerfield Private Design Fund Iii, L.p. |
*Possible Member of 10% Group |
– – • |
2021-01-06 |
4 |
S |
$22.47 |
$652,703 |
I/I |
(29,039) |
907,252 |
|
52% |
|
| Raffin Thomas A. |
Director |
– • – |
2020-04-03 |
4 |
A |
$0.00 |
$0 |
D/D |
709 |
7,889 |
|
- |
|
| Mccracken Joseph S |
Director |
– • – |
2020-04-03 |
4 |
A |
$0.00 |
$0 |
D/D |
709 |
709 |
|
- |
|
| Cunningham Emmett |
Director |
– • – |
2020-04-03 |
4 |
A |
$0.00 |
$0 |
D/D |
709 |
709 |
|
- |
|
| Zoth Lota S |
Director |
– • – |
2020-04-03 |
4 |
A |
$0.00 |
$0 |
D/D |
709 |
1,820 |
|
- |
|
| Johnson Chad Allen |
Director |
– • – |
2020-04-03 |
4 |
A |
$0.00 |
$0 |
D/D |
709 |
709 |
|
- |
|
| Lalande Kevin M. |
Director |
– • – |
2020-04-03 |
4 |
A |
$0.00 |
$0 |
D/D |
709 |
709 |
|
- |
|
| Lawley Lori D |
Principal Accounting Officer |
• – – |
2020-04-01 |
4 |
A |
$0.00 |
$0 |
D/D |
4,500 |
4,842 |
|
- |
|
| Kennedy Eugene P. |
Chief Medical Officer |
• – – |
2020-04-01 |
4 |
A |
$0.00 |
$0 |
D/D |
9,000 |
10,484 |
|
- |
|
| Powers Bradley J |
General Counsel |
• – – |
2020-04-01 |
4 |
A |
$0.00 |
$0 |
D/D |
4,500 |
4,555 |
|
- |
|
| Mckew John C. |
Chief Scientific Officer |
• – – |
2020-04-01 |
4 |
A |
$0.00 |
$0 |
D/D |
13,000 |
13,000 |
|
- |
|
| Langren Carl W. |
Chief Financial Officer |
• – – |
2020-04-01 |
4 |
A |
$0.00 |
$0 |
D/D |
9,000 |
11,238 |
|
- |
|
| Hawkins Richard J |
Chief Executive Officer |
• • – |
2020-04-01 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
744,575 |
|
- |
|
| Deerfield Private Design Fund Iii, L.p. |
10% Owner |
– – • |
2020-03-18 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
936,169 |
|
78% |
|
| Kennedy Eugene P. |
Chief Medical Officer |
• – – |
2020-01-04 |
4 |
D |
$2.21 |
$831 |
D/D |
(376) |
13,721 |
|
- |
|
| Langren Carl W. |
Chief Financial Officer |
• – – |
2020-01-04 |
4 |
D |
$2.21 |
$621 |
D/D |
(281) |
20,144 |
|
- |
|
| Zoth Lota S |
Director |
– • – |
2020-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
2,100 |
10,006 |
|
- |
|
| Powers Bradley J |
Principal Executive Officer |
• – – |
2019-08-24 |
4 |
D |
$1.59 |
$121 |
D/D |
(76) |
503 |
|
- |
|
| Powers Bradley J |
Principal Executive OfficerOff |
• – – |
2019-08-03 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
250 |
|
- |
|
| Powers Bradley J |
Principal Executive OfficerOff |
• – – |
2019-08-03 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
579 |
|
- |
|
| Kennedy Eugene P. |
Chief Medical Officer |
• – – |
2019-06-23 |
4 |
D |
$1.57 |
$564 |
D/D |
(359) |
14,097 |
|
- |
|
| Link Charles J. Jr. |
Chairman of the Board and CEO |
• • – |
2019-01-04 |
4 |
D |
$1.55 |
$9,154 |
D/D |
(5,906) |
250,801 |
|
- |
|
303 Records found
|
|
Page 5 of 13 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.04 (1.75%) 
